Likewise, APTO-253 treatment of IPF fibroblasts increased KLF4 expression (Figure 3M) and significantly reduced their high baseline expression of α-SMA mRNA and protein (Figure 3, N and O, and Supplemental Figure 7B). The gene discussed is ACTA1; the disease is idiopathic pulmonary fibrosis.